The competitive market for antiplatelets and thrombolytics: can a new entrant succeed?

The current lack of available antiplatelet and thrombolytic agents, the limitations of existing products, the possibility of value-pricing, and the sheer number of pitential candidates for therapy all combine to produce a market with tremendous potential. Given these very significant incentives, it is no wonder that so many pharmaceutical companies have chosen to pursue research in the antithrombotic field.